Obermatt

Pentixapharm

GER:PTP · DE000A40AEG0
Health Care Equipment & SuppliesX-Small

360

22
Medium confidence — indicative
Profit price74
Owner Earnings Yield1
Dividend Yield1
Price/Sales3
Price/Book67
Return on Capital5
Cash Return on Capital6
Return on Equity8
Profit margins1
Accruals43
Owner Earnings Margin1
Sales growth1
Profit growth26
Reinvestment4
Price momentum41
Debt load67
Refinancing23
Debt Payback1
Liquidity1
Analyst ratings100
Expectations trend50
Market mood59
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Pentixapharm doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryGermany
IndustryHealth Care Equipment & Supplies
SizeX-Small
TypePublic Company
ExchangeXTRA
Founded2024
ISINDE000A40AEG0
Last UpdateApr 2, 2026
Themes
Health DiagnosticsHematologyCardiovascularOncology

Description

Analysis

Weak and unloved

Pentixapharm Holding AG is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is mixed and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
6
2026

All-time high

20

Mar 2026

All-time low

6

Jun 2026

Average rank

13

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
3
Price/Earnings
Price/Book
67
Dividend Yield
1
Value (overall)
18

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Pentixapharm with its peers
Anbio Biotechnology
NMQ:NNNN
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Pharming
AEX:PHARM
77
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
NewAmsterdam Pharma Company
NMQ:NAMS
16
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
PolyPid
NAQ:PYPD
26
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
GH Research
NMQ:GHRS
57
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →